Akari Therapeutics (AKTX) Assets Average (2012 - 2026)

Akari Therapeutics has disclosed Assets Average across 13 years of filings, most recently posting $40.9 million for Q1 2026.

• Assets Average for Q1 2026 came in at $40.9 million, down 19.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.9 million (down 19.44% YoY), and the FY2025 annual result was $49.2 million, up 79.28% from the prior year.
• Assets Average came in at $40.9 million for Q1 2026 at Akari Therapeutics, down from $46.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $50.9 million in Q2 2025 to a low of $3.6 million in Q1 2024.
• The 4-year median for Assets Average is $33.8 million (2024), against an average of $28.8 million.
• Across the five-year window, Assets Average soared 1324.46% in 2025 and retreated 19.44% in 2026, its largest moves.
• Akari Therapeutics' Assets Average stood at $12.7 million in 2022, then soared by 109.17% to $26.6 million in 2024, then surged by 75.0% to $46.6 million in 2025, then dropped by 12.32% to $40.9 million in 2026.
• The last three Assets Average figures came in at $40.9 million (Q1 2026), $46.6 million (Q4 2025), and $48.1 million (Q3 2025), per Business Quant data.